Signalisation JAK/STAT
Sous-catégories appartenant à la catégorie "Signalisation JAK/STAT"
363 produits trouvés pour "Signalisation JAK/STAT"
Tyk2-IN-10
CAS :Tyk2-IN-10 acts as an inhibitor of the Tyrosine Kinase 2 (Tyk2)-mediated signaling pathway, which plays a role in inflammation regulation.Formule :C25H27N5O3Couleur et forme :SolidMasse moléculaire :445.51Londamocitinib
CAS :Londamocitinib (JAK1-IN-7) is a selective and potent JAK1 inhibitor with anti-inflammatory activity.Formule :C28H31F2N7O4SDegré de pureté :98.64% - 99.56%Couleur et forme :SolidMasse moléculaire :599.65Ref: TM-T11706
1mg170,00€5mg416,00€1mL*10mM (DMSO)537,00€10mg567,00€25mg858,00€50mg1.108,00€100mg1.485,00€Tyk2-IN-14
CAS :Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Formule :C22H21N9O2Couleur et forme :SolidMasse moléculaire :443.4615(R)-Lipoxin A4
CAS :Lipid-derived lipoxins are produced at the site of vascular and mucosal inflammation where they down-regulate polymorphonuclear leukocyte recruitment andFormule :C20H32O5Couleur et forme :SolidMasse moléculaire :352.47JDTic
CAS :JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Formule :C28H39N3O3Couleur et forme :SolidMasse moléculaire :465.63(3R,4S)-Tofacitinib
CAS :(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Formule :C16H20N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :312.37JAK2-IN-9
CAS :Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.
Formule :C20H24N6O2SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :412.51JAK1-IN-10
CAS :JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].
Formule :C15H17N7Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :295.34JAK-IN-34
CAS :JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,
Formule :C27H26N6ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :450.53STAT3-IN-18
CAS :STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and
Formule :C18H24Cl2N2O6PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :630.38DPP
CAS :DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating
Formule :C36H40Cl2N2O10PtDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :926.7JAK1-IN-11
CAS :JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.
Formule :C26H36N6O4SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :528.67JAK-IN-27
CAS :JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM
Formule :C20H21F2N7ODegré de pureté :98%Couleur et forme :SolidMasse moléculaire :413.42
